| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | HUMA | Common Stock | Sale | -$5.57M | -717K | -11.57% | $7.78 | 5.47M | May 31, 2024 | By Ayabudge LLC | F1, F2 |
| transaction | HUMA | Common Stock | Sale | -$832K | -93.2K | -1.7% | $8.93 | 5.38M | May 31, 2024 | By Ayabudge LLC | F1, F3, F4 |
| transaction | HUMA | Common Stock | Sale | -$1.41M | -190K | -3.53% | $7.42 | 5.19M | Jun 3, 2024 | By Ayabudge LLC | F1, F5 |
| transaction | HUMA | Common Stock | Sale | -$13.5K | -1.85K | -0.04% | $7.28 | 5.19M | Jun 4, 2024 | By Ayabudge LLC | F1, F6 |
| holding | HUMA | Common Stock | 238K | May 31, 2024 | Direct | ||||||
| holding | HUMA | Common Stock | 510K | May 31, 2024 | By spouse | ||||||
| holding | HUMA | Common Stock | 1.15M | May 31, 2024 | By The Niklason Living Trust |
| Id | Content |
|---|---|
| F1 | The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions. |
| F2 | The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $7.405 to $8.40. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F3 | A portion of this sale is matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, against a portion of the purchase by Dr. Niklason of 2,050 shares of the Issuer's common stock on June 3, 2024, at a price per share of $7.37. The Reporting Person has paid the Issuer $4,007.76, representing the full amount of profit realized in connection with this sale. |
| F4 | The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $8.41 to $9.345. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F5 | The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $7.25 to $7.625. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F6 | The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $7.265 to $7.33. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |